MEHMET ERGİN, METİN ÖZKAN, MERAL ILGAZ ERGİN, AHU CEPHE
Journal of Clinical Practice and Research - 2023;45(2):165-171
Aim: In this study, it was aimed to examine the mutation panel studied with liquid biopsy in diagnosed lung adenocancer patients and to investigate its relationship with survival. Material and methods: Twenty-four diagnosed lung adenocarcinoma patients between the ages of 18-80, metastatic and who had not received chemotherapy yet were included in the study. The cfDNAs (cell-free DNA) isolated from the patient’s blood were analyzed using the next generation sequencing commercial kit 56G Oncology Panel. SOPHiA DDM® (Saint-Sulpice, Switzerland) bioinformatics program was used for the classification of detected genetic variants. The patients were followed for 3 years in terms of survival. R Version 4.1.3 (https: //rstudio.com/) and TURCOSA Analytical (https: //turcosa.com.tr/) software was used for the statistical analysis. Results: Mutation was found in liquid biopsy in 16 (66.7%) of the patients. In 7 (29.1%) patients, more than one mutation was detected in liquid biopsy. When the relationship between the variables and mortality was examined in the cases included in the study, there was a significant relationship between age and mortality (p=0.029) and mortality was increasing with aging. In the survival analysis, no statistically significant relationship was found between gender, smoking status, mutation status and survival according to Kaplan-Meier graphs and log-rank tests. Conclusion: As a result, driver mutation was detected in 66.7% of the patients included in our study. Driver mutations are targets for treatments, and liquid biopsy may play a crucial role in the course of lung adenocancer to detect the driver mutations.
